Akebia Therapeutics (AKBA)
(Delayed Data from NSDQ)
$1.34 USD
+0.01 (0.75%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $1.33 -0.01 (-0.75%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
Cash flow Statements
Fiscal Year End for Akebia Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -51.93 | -92.56 | -282.84 | -383.46 | -279.66 |
Depreciation/Amortization & Depletion | 37.63 | 37.70 | 37.96 | 149.07 | 37.83 |
Net Change from Assets/Liabilities | -20.73 | -1.44 | -108.42 | -13.67 | -99.07 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 11.64 | -16.85 | 100.34 | 137.67 | 83.46 |
Net Cash From Operating Activities | -23.38 | -73.15 | -252.97 | -110.39 | -257.44 |
Property & Equipment | 0.00 | -0.11 | -0.06 | -0.32 | -6.66 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 40.00 | -39.69 | 217.83 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 0.00 | -0.11 | 39.94 | -40.00 | 211.18 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 6.79 | 7.60 | 88.95 | 211.75 | 26.30 |
Issuance (Repayment) of Debt | -32.00 | -33.00 | 0.00 | 19.98 | 62.67 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 40.00 | 44.78 | 0.00 | 0.00 |
Net Cash from Financing Activities | -25.21 | 14.60 | 133.73 | 231.72 | 88.97 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -48.59 | -58.67 | -79.29 | 81.33 | 42.71 |
Cash at Beginning of Period | 93.17 | 151.84 | 231.13 | 149.80 | 107.10 |
Cash at End of Period | 44.58 | 93.17 | 151.84 | 231.13 | 149.80 |
Diluted Net EPS | -0.28 | -0.51 | -1.70 | -2.77 | -2.36 |
Fiscal Year End for Akebia Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -51.93 | -52.54 | -38.05 | -26.22 |
Depreciation/Amortization & Depletion | NA | 37.63 | 28.22 | 18.82 | 9.41 |
Net Change from Assets/Liabilities | NA | -20.73 | -4.52 | -0.31 | -3.84 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 11.64 | 7.76 | 5.64 | 3.11 |
Net Cash From Operating Activities | NA | -23.38 | -21.08 | -13.91 | -17.54 |
Property & Equipment | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 6.79 | 0.08 | 0.03 | 0.03 |
Issuance (Repayment) of Debt | NA | -32.00 | -24.00 | -24.00 | -16.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | NA | -25.21 | -23.92 | -23.97 | -15.97 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | -48.59 | -44.99 | -37.88 | -33.50 |
Cash at Beginning of Period | NA | 93.17 | 93.17 | 93.17 | 93.17 |
Cash at End of Period | NA | 44.58 | 48.18 | 55.29 | 59.67 |
Diluted Net EPS | NA | 0.00 | -0.08 | -0.06 | -0.14 |